Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three pharmaceutical agents—gabapentin, dexamethasone, and ketamine—used together primarily for multimodal analgesia in perioperative and postoperative pain management. Gabapentin is an anticonvulsant that modulates voltage-gated calcium channels to reduce neuropathic pain. Dexamethasone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties, acting via the glucocorticoid receptor to inhibit pro-inflammatory pathways. Ketamine is a dissociative anesthetic that acts as an NMDA receptor antagonist, providing analgesia and anesthesia by blocking excitatory neurotransmission involved in pain perception. The combination leverages different mechanisms of action to provide synergistic or additive effects on pain control while potentially reducing opioid requirements[1][3][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gabapentin + dexamethasone + ketamine.